CN Bio's Series B Funding Boosts OOC Technology Expansion
April 23, 2024, 9:32 pm
CN Bio, a pioneer in microphysiological systems, secures $21 million in Series B funding to accelerate product development and global market expansion. The investment, led by Bayland Capital and CN Innovations Holdings Ltd, will drive innovation in Organ-on-a-Chip (OOC) technology, revolutionizing drug discovery and reducing reliance on animal models. CEO Dr. Paul Brooks highlights the industry's recognition of OOC technology's potential to streamline drug development processes and deliver faster, cost-effective solutions with minimal animal experimentation. This strategic funding marks a significant milestone in CN Bio's journey towards shaping the future of preclinical drug discovery.